{"title":"免疫疗法-吸入性过敏的次优疗效的原因","authors":"M. Nittner-Marszalska","doi":"10.5114/PJA.2021.104618","DOIUrl":null,"url":null,"abstract":"Allergen immunotherapy (AIT) has proven efficacy in IgE-dependent respiratory diseases. When AIT is con-ducted continnuosly for 3 years, it confers long-term clinical benefits after cessation of treatment. While multiple studies confirm high efficacy of AIT, there are some patients who do not respond to this therapy (“non-responders”) or find its results non-satisfactory (“poor-responders”). What factors may be responsible for lack of a therapeutic success of AIT or the therapy’s not fully optimal result? How to predict AIT treatment failures? Can biomarkers facilitate the prediction? How to identify patients who may turn out to be treatment failures? The article sets forth causes of AIT failures: wrong diagnosis of the underlying allergic disease, selection of a clinically non-important allergen for AIT, lack of sensibilization to the major allergen and badly performed AIT. In regard to AIT success of failure, additionally addressed is the issue of heterogeneity of molecular profiles and the sensibilization to clinically important molecules like Der p 23.","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Immunotherapy – the causes of sub-optimal efficacy in inhaled allergies\",\"authors\":\"M. Nittner-Marszalska\",\"doi\":\"10.5114/PJA.2021.104618\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Allergen immunotherapy (AIT) has proven efficacy in IgE-dependent respiratory diseases. When AIT is con-ducted continnuosly for 3 years, it confers long-term clinical benefits after cessation of treatment. While multiple studies confirm high efficacy of AIT, there are some patients who do not respond to this therapy (“non-responders”) or find its results non-satisfactory (“poor-responders”). What factors may be responsible for lack of a therapeutic success of AIT or the therapy’s not fully optimal result? How to predict AIT treatment failures? Can biomarkers facilitate the prediction? How to identify patients who may turn out to be treatment failures? The article sets forth causes of AIT failures: wrong diagnosis of the underlying allergic disease, selection of a clinically non-important allergen for AIT, lack of sensibilization to the major allergen and badly performed AIT. In regard to AIT success of failure, additionally addressed is the issue of heterogeneity of molecular profiles and the sensibilization to clinically important molecules like Der p 23.\",\"PeriodicalId\":7469,\"journal\":{\"name\":\"Alergologia Polska - Polish Journal of Allergology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alergologia Polska - Polish Journal of Allergology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5114/PJA.2021.104618\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alergologia Polska - Polish Journal of Allergology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/PJA.2021.104618","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0
摘要
过敏原免疫疗法(AIT)已被证明对ige依赖性呼吸系统疾病有效。当AIT持续进行3年,它可以在停止治疗后获得长期的临床益处。虽然多项研究证实了AIT的高疗效,但仍有一些患者对这种治疗没有反应(“无反应”)或发现其结果不令人满意(“不良反应”)。什么因素可能导致AIT治疗不成功或者治疗效果不理想?如何预测AIT治疗失败?生物标志物能促进预测吗?如何识别治疗失败的病人?本文阐述了AIT失败的原因:对潜在过敏疾病的错误诊断,临床上对AIT的非重要过敏原的选择,对主要过敏原的不敏感以及AIT的不良执行。关于AIT的成功或失败,另外要解决的问题是分子谱的异质性和对临床重要分子(如Der p 23)的敏感性。
Immunotherapy – the causes of sub-optimal efficacy in inhaled allergies
Allergen immunotherapy (AIT) has proven efficacy in IgE-dependent respiratory diseases. When AIT is con-ducted continnuosly for 3 years, it confers long-term clinical benefits after cessation of treatment. While multiple studies confirm high efficacy of AIT, there are some patients who do not respond to this therapy (“non-responders”) or find its results non-satisfactory (“poor-responders”). What factors may be responsible for lack of a therapeutic success of AIT or the therapy’s not fully optimal result? How to predict AIT treatment failures? Can biomarkers facilitate the prediction? How to identify patients who may turn out to be treatment failures? The article sets forth causes of AIT failures: wrong diagnosis of the underlying allergic disease, selection of a clinically non-important allergen for AIT, lack of sensibilization to the major allergen and badly performed AIT. In regard to AIT success of failure, additionally addressed is the issue of heterogeneity of molecular profiles and the sensibilization to clinically important molecules like Der p 23.
期刊介绍:
Alergologia Polska - Polish Journal of Allergology is aimed mainly at allergologists, but also medical doctors working in related fields, such as otolaryngology, pulmonology, and dermatology. The main goal of the journal is to ensure rapid publication of important research papers and interesting case studies from the following areas: allergology, diagnostics, therapy of allergic diseases, in particular in the area of immunotherapy, rhinitis, asthma. The Editorial Board accepts for publication original papers, case studies and letters to the Editor. We also publish review articles (both commissioned and those agreed upon with the Editor-in-Chief), articles dealing with standards of medical practice, as well as special issues. The journal is published quarterly. We guarantee short review times (up to two weeks) and immediate publication on-line upon Editor acceptance.